No radiation therapy =< weeks before pre-registration No prior radiation therapy for bone metastasis within weeks, any other radiation therapy within weeks prior to registration Washout period should be at least weeks for prior chemotherapy or radiation therapy Subject is within weeks of completion of radiation. At least weeks since prior treatment (chemotherapy, radiation therapy, hormonal therapy) Radiation therapy for breast cancer within weeks of dosing and planning to have radiation therapy during participation in this study. Radiation therapy within weeks of enrollment At least weeks after the last dose of chemotherapy or radiation therapy; weeks for mitoxantrone or mitomycin therapy Prior radiation therapy within weeks prior to the first dose of the study regimen Any radiation therapy in prior weeks Radiation therapy less than or equal to weeks prior to registration Prior radiation therapy or chemotherapy within weeks prior cycle , day , monoclonal antibody therapy within weeks Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before planned first dose of study drug. Systemic treatment with radionuclides within weeks before planned first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Had therapeutic radiation therapy or major surgery within weeks before study drug treatment or palliative radiation therapy within weeks before study drug treatment. Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before the first dose of study treatment. Systemic treatment with radionuclides within weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Participants must be >= weeks since any prior radiation, including central nervous system (CNS) radiation Radiation therapy within weeks of study treatment Participants must be >= weeks since any prior radiation, including central nervous system (CNS) radiation Radiation within weeks prior to registration At least weeks (wks) since prior radiation Radiation therapy in the previous weeks prior to first dose. >= weeks off radiation therapy Recent prior therapy:\r\n* Systemic chemotherapy =< weeks ( weeks for clofarabine or nitrosoureas) or radiation therapy =< weeks prior to apheresis;\r\n** Exceptions:\r\n*** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such;\r\n*** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least weeks prior to starting apheresis;\r\n*** Patients who are on standard ALL maintenance type chemotherapy (vincristine, -mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for patients with Philadelphia chromosome positive [Ph+] ALL) may be enrolled provided that chemotherapy is discontinued at least week prior to apheresis\r\n*** Subjects receiving steroids may be enrolled, provided there has been no increase in dose for at least week prior to starting apheresis;\r\n*** For radiation therapy: radiation therapy must have been completed at least weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port Radiation therapy to a study target tumor within year prior to enrollment, or any radiation therapy within weeks prior to enrollment Minimum interval since completion of radiation treatment is weeks STRATUM A: Participants must have had their last fraction of radiation at least weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least weeks prior to study enrollment STRATUM B: Participants must have had their last fraction of radiation at least weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least weeks prior to study enrollment STRATUM C: Participants must have had their last fraction of radiation at least weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least weeks prior to study enrollment Treatment with radiation therapy within weeks Radiation therapy within weeks (if single fraction of radiotherapy within weeks) of enrollment (day visit) Subjects who have had radiation therapy within weeks prior to first dose of drug Subjects must be at least weeks from prior anti-lymphoma therapy (including radiation therapy) Prior major surgical procedure or radiation therapy within weeks of the first dose of study treatment (this does not include limited course of radiation used for management of bone pain within days of first dose of study therapy) Radiation treatment must begin >= weeks and =< weeks after surgery Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before the first dose of study treatment; systemic treatment with radionuclides within weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Patients must be >= weeks from most recent systemic therapy or radiation therapy Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within weeks prior to initiation of study treatment Radiation therapy within weeks (within weeks, if single fraction of radiotherapy) before day . Patients who have had chemotherapy or radiation therapy within weeks prior to beginning protocol therapy No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment Radiation therapy within weeks prior to randomization and not recovered to baseline from any AE due to radiation Any chemotherapy or radiation therapy within weeks of the first dose of study drug The following minimum intervals are required between prior treatment and initiation of study therapy:\r\n* Cytotoxic chemotherapy: weeks\r\n* Molecularly targeted therapy or immunotherapy: weeks\r\n* Conventional fractionated radiation therapy: weeks\r\n* Stereotactic radiation therapy: week\r\n* Major surgery: weeks Major surgery < weeks or radiation therapy < weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated\r\n* Radiotherapy is defined as whole brain radiation, external beam radiation therapy (EBRT), or stereotactic brain radiation (SBRT) Radiation therapy within four weeks prior to administration of the first dose of ARQ Radiation therapy within weeks of study enrollment (exception is radiotherapy expansion arm which requires radiation treatment within week period) Local Skin Radiation Therapy (< % skin surface): weeks Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before the first dose of study treatment; systemic treatment with radionuclides within weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Radiation therapy for bone metastases within weeks, other external radiation therapy within weeks of enrollment Radiation or chemotherapy within weeks of enrollment Subject has had radiation therapy to the tumor selected for research collection, or has had radiation therapy to any site within weeks prior to study day Patients who have had chemotherapy or radiation =< weeks of registration Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least weeks prior to enrollment, or after surgical resection performed at least weeks prior to enrollment Radiation therapy for bone metastasis within weeks, or any other external radiation therapy within weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Radiation therapy must begin within weeks of surgery > weeks since prior radiation, surgery or chemotherapy Minimum interval since completion of radiation treatment is weeks Screening magnetic resonance imaging (MRI) must be obtained at least weeks after any salvage surgery, and at least weeks after radiation therapy, or at least weeks after radiation for a new lesion outside the prior primary radiation field unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are weeks apart Radiation therapy within weeks before the first dose of study treatment At least weeks since the completion of radiation therapy to a total of >= Gy Patients must have failed prior radiation therapy and must have an interval of greater than or equal to weeks from the completion of radiation therapy to registration; except if patients underwent surgery within weeks and pathology is consistent with recurrent tumor > weeks since prior radiation, surgery or chemotherapy Radiation Therapy: Hepatic radiation within weeks of PV- administration. Prior radiation within weeks of study registration Conventional chemotherapy or radiation within weeks. Conventional chemotherapy or radiation within weeks. Radiation therapy within weeks of Day No radiation therapy to targeted (most painful) tumors in the past two weeks Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before the first dose of study treatment; systemic treatment with radionuclides within weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Subjects who have had radiation therapy within weeks prior to first dose of drug Prior chemoembolization or radiation therapy (including Y) must be performed at least weeks before study enrollment Has had radiation therapy within weeks of the first protocol treatment At least weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least weeks Radiation therapy within weeks prior to enrollment Recent prior therapy:\r\n* Systemic chemotherapy =< weeks ( weeks for nitrosoureas) or radiation therapy =< weeks prior to apheresis; exceptions: \r\n** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such; \r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least weeks prior to starting apheresis; \r\n** Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided they meet all other eligibility criteria; \r\n** Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least weeks prior to starting apheresis; \r\n** For radiation therapy: radiation therapy must have been completed at least weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port Radiation therapy within weeks prior to randomization on this study and not recovered to baseline from adverse events due to radiation therapy Subject has radiation therapy within weeks prior to the first study dose. Radiation therapy within weeks prior to screening. Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least weeks before the start of therapy; Radiation therapy within weeks of registration Radiation therapy (except palliative to relieve bone pain) within weeks of study entry. Whole brain radiation must have completed at least weeks prior to study entry. Radiation therapy within weeks ( weeks for radiation for bone metastases) or radionuclide treatment within weeks of randomization. Prior radiation therapy within weeks of infusion At least weeks from end of radiation therapy Radiation therapy (other than radiation to bony metastases) as cancer therapy weeks prior to Day (or ? weeks if the recurrence is outside of the prior radiation field). Subject has radiation therapy within weeks prior to the first study dose. Radiation therapy for bone metastases within weeks, other external radiation therapy within weeks of enrollment Radiation therapy to bone within weeks before enrollment; Radiation therapy =< weeks prior to randomization Radiation or chemotherapy within weeks of enrollment Patient has had radiation therapy within weeks of beginning study treatment No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy within the last weeks. Radiation therapy for symptomatic relief is allowed within the last weeks. Conventional chemotherapy or radiation within weeks. No radiation therapy =< weeks prior to registration Patients must be at least two weeks from prior radiation therapy (RT) At least weeks since prior chemotherapy or radiation therapy Chemotherapy, radiation therapy, or ablative therapy within weeks of randomization Radiation therapy within weeks before first dose. Radioimmunotherapy within weeks before first dose. Subject has radiation therapy within weeks prior to the first study dose. No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment Patients must have failed prior radiation therapy and must have an interval of greater than or equal to weeks from the completion of radiation therapy to study entry Radiation therapy within weeks prior to first dose Radiation therapy within weeks prior to first dose. Localized radiation therapy within week prior to first dose. Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least weeks prior to enrollment, or after surgical resection performed at least weeks prior to enrollment Prior radiation therapy within weeks and radionuclide therapy within weeks of enrollment Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior weeks) Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior weeks) If palliative radiation to non-breast sites is required prior to initiation of systemic therapy, scans may be completed within weeks prior to or weeks following the start of radiation therapy Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ Radiation therapy =< weeks prior to registration Prior palliative radiation therapy less than weeks prior to administration of study treatment or prior whole brain radiation therapy (WBRT) less than weeks prior to study treatment Radiation treatment within weeks. Radiation therapy within weeks prior to the first dose of study medication Therapeutic radiation therapy or major surgery within weeks before study drug treatment; or palliative radiation within weeks before study drug treatment Ongoing radiation therapy or radiation therapy administered within weeks of enrollment At least weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least weeks Radiation therapy or surgery in the past weeks =< weeks since radiation therapy Radiation therapy within weeks. Radiation and surgery within weeks prior to treatment in this study Subject has had radiation therapy within weeks prior to the first study dose. Must have stable neurologic status following local therapy (surgery or radiation) for at least weeks after completion of the definitive therapy AND Subject has had radiation therapy within weeks prior to the first study dose Radiation treatment within weeks. Radiation therapy or immunotherapy in the previous four weeks; localized radiation therapy within week prior to first dose Radiation therapy within weeks before first dose Radiation therapy within weeks (if single fraction of radiotherapy within weeks) of Day visit, or radionuclide therapy within weeks of Day Radiation therapy to any Study Lesion within weeks of initial study treatment. The subject has received radiation therapy within weeks (=< weeks for palliative radiation therapy) Radiation therapy for bone or brain metastasis within weeks, any other external radiation therapy within weeks of first dose of study drug; systemic treatment with radionuclides within weeks; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible Patients must be at least weeks from the completion of any radiation therapy Radiation therapy as cancer therapy within weeks, or palliative radiation to bony metastases within weeks, prior to starting study treatment Interval from radiation therapy at least weeks and no more than year Treatment with radiation within weeks Prior radiation therapy of the index tumor < weeks prior to screening At least weeks since prior chemotherapy, radiation treatment and/or surgery Focal radiation ? weeks Radiation therapy for bone metastasis within weeks, any other external radiation therapy within weeks before randomization. Systemic treatment with radionuclides within weeks before randomization. Subjects with complications from prior radiation therapy are not eligible and AEs must return to baseline or ? Grade . weeks since last chemotherapy or therapeutic radiation therapy Prior chemotherapy within weeks; prior immunotherapy or biologic therapy within weeks; prior radiation therapy within weeks Therapeutic radiation therapy or major surgery within weeks before study drug treatment or palliative radiation therapy within weeks before study drug treatment. chemotherapy or radiation therapy within three weeks